# The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Study · id `cardio:ct-nct05836987` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05836987](<https://clinicaltrials.gov/study/NCT05836987>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05836987

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5350 participants.

## Technical summary

Registry record NCT05836987. Randomized; single masking; primary purpose prevention. Start 2023-07-13 (actual); primary completion 2029-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 5350 participants (planned count; ClinicalTrials.gov record NCT05836987, source copy `cardio:ctgov-nct05836987-2026-11-03`, retrieved 2026-11-18)
- Started: 2023-07-13 (actual) (ClinicalTrials.gov record NCT05836987, source copy `cardio:ctgov-nct05836987-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2029-07-31 (anticipated) (ClinicalTrials.gov record NCT05836987, source copy `cardio:ctgov-nct05836987-2026-11-03`, retrieved 2026-11-18)
- Completion: 2029-07-31 (anticipated) (ClinicalTrials.gov record NCT05836987, source copy `cardio:ctgov-nct05836987-2026-11-03`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT05836987, source copy `cardio:ctgov-nct05836987-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05836987-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- Acronym: REACT-AF
- Condition: Atrial Fibrillation
- Intervention (Device): AFSW Guided DOAC
- Intervention (Drug): Continuous DOAC therapy
- Lead sponsor: Johns Hopkins University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH
- Collaborator: Northwestern University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Johns Hopkins University (`cardio:org-johns-hopkins-university`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)
- Registry lists this organization as a collaborator: Northwestern University (`cardio:org-northwestern-university`)

## Provenance

Content hash: a21fd9f6fa247ac0a5bfbe9edb89b6556f8ddf6f2edf4118e144780144178c57
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
